Endothelial Progenitor Cells

Circulation Research - Tập 95 Số 4 - Trang 343-353 - 2004
Carmen Urbich1, Stefanie Dimmeler1
1From Molecular Cardiology, Department of Internal Medicine IV, University of Frankfurt, Frankfurt, Germany.

Tóm tắt

Infusion of different hematopoietic stem cell populations and ex vivo expanded endothelial progenitor cells augments neovascularization of tissue after ischemia and contributes to reendothelialization after endothelial injury, thereby, providing a novel therapeutic option. However, controversy exists with respect to the identification and the origin of endothelial progenitor cells. Overall, there is consensus that endothelial progenitor cells can derive from the bone marrow and that CD133/VEGFR2 cells represent a population with endothelial progenitor capacity. However, increasing evidence suggests that there are additional bone marrow-derived cell populations (eg, myeloid cells, “side population” cells, and mesenchymal cells) and non-bone marrow-derived cells, which also can give rise to endothelial cells. The characterization of the different progenitor cell populations and their functional properties are discussed. Mobilization and endothelial progenitor cell-mediated neovascularization is critically regulated. Stimulatory (eg, statins and exercise) or inhibitory factors (risk factors for coronary artery disease) modulate progenitor cell levels and, thereby, affect the vascular repair capacity. Moreover, recruitment and incorporation of endothelial progenitor cells requires a coordinated sequence of multistep adhesive and signaling events including adhesion and migration (eg, by integrins), chemoattraction (eg, by SDF-1/CXCR4), and finally the differentiation to endothelial cells. This review summarizes the mechanisms regulating endothelial progenitor cell-mediated neovascularization and reendothelialization.

Từ khóa


Tài liệu tham khảo

10.1126/science.275.5302.964

10.1182/blood.V92.2.362

10.1182/blood.V95.3.952.003k27_952_958

10.1182/blood.V95.10.3106

10.1111/j.1749-6632.2003.tb03242.x

10.1182/blood.V93.9.2951

10.1172/JCI8071

10.1016/S0008-6363(00)00270-4

10.1161/01.cir.0000096483.29777.50

10.1038/nm963

10.1073/pnas.0536882100

10.1161/01.res.0000070067.64040.7c

10.1161/01.res.0000099245.08637.ce

10.1161/01.cir.0000058702.69484.a0

10.1073/pnas.97.7.3422

10.1161/01.res.0000105569.77539.21

10.1161/01.CIR.0000080288.30567.86

10.1038/nm0302-194

10.1172/JCI12150

10.1172/JCI0214327

10.1016/S0092-8674(03)00687-1

10.1172/JCI6889

10.1161/circ.103.5.634

10.1038/86498

10.1172/JCI8296

10.1016/S0140-6736(02)09670-8

10.1161/01.cir.0000043246.74879.cd

10.1038/nm1101-1194

10.1172/JCI9087

10.1038/7434

10.1161/01.cir.0000055313.77510.22

10.1038/nm0602-607

10.1161/01.atv.0000114236.77009.06

10.1016/S0008-6363(02)00615-6

10.1161/01.res.0000057997.77714.72

10.1152/ajpheart.01098.2001

10.1161/res.87.9.728

10.1172/JCI200113131

10.1016/S0301-472X(02)00867-6

10.1126/science.1082504

10.1038/nm871

10.1161/res.90.3.284

10.1161/01.str.0000014925.09415.c3

10.1111/j.1750-3639.2003.tb00487.x

10.1161/01.res.0000110419.50982.1c

10.1161/res.88.2.167

10.1038/nm948

10.1038/nm0195-27

10.1038/269804a0

10.1091/mbc.3.2.211

10.1161/01.cir.0000018166.84319.55

10.1161/01.res.0000083812.30141.74

10.1038/nm0901-1035

10.1161/01.cir.0000096490.16596.a6

10.1161/01.cir.0000105722.96112.67

10.1161/01.cir.0000106161.43954.df

10.1007/s003950170073

10.1161/01.cir.0000082924.75945.48

10.1056/NEJMoa022287

10.1161/hh1301.093825

10.1161/01.cir.0000039526.42991.93

10.2337/diabetes.53.1.195

10.1016/S0002-9440(10)63136-7

10.1161/circ.103.24.2885

10.1161/01.CIR.0000109141.48980.37

10.1182/blood-2003-05-1595

10.1016/S0092-8674(02)00754-7

10.1056/NEJM200003023420904

10.1023/A:1012808525370

10.1161/circ.103.23.2776

10.1161/res.86.12.1198

Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiological stimulus for endothelial progenitor cell mobilization. Blood. 2003; 17: 17.

10.1182/blood-2003-04-1284

10.1111/j.1749-6632.2001.tb03572.x

10.1084/jem.193.9.1005

10.1172/JCI200113152

10.1161/01.cir.0000106906.56972.83

10.1161/01.cir.0000077911.81151.30

10.1038/79510

10.1084/jem.20021659

10.1016/0092-8674(94)90337-9

10.1182/blood.V84.7.2068.2068

10.1038/labinvest.3780446

10.1111/j.1365-2141.1990.tb06363.x

10.1182/blood.V97.10.3283

10.1172/JCI7615

10.1161/01.res.0000013835.53611.97

10.1164/rccm.2105034

10.1128/MCB.23.24.9349-9360.2003

10.1111/j.1749-6632.2001.tb03577.x

10.1084/jem.20011284

Kimura T, Boehmler AM, Seitz G, Kuci S, Wiesner T, Brinkmann V, Kanz L, Mohle R. The sphingosine 1-phosphate (S1P) receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells. Blood. 2004; 26: 26.

10.1182/blood-2002-02-0486

10.1016/S0140-6736(03)14232-8

10.1161/01.cir.0000095788.78169.af

10.1038/380439a0

10.1038/376066a0

10.1038/376062a0

10.1182/blood-2003-02-0634

Zippo A, De Robertis A, Bardelli M, Galvagni F, Oliviero S. Identification of Flk-1-target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood. 2004; 24: 24.

Bompais H, Chagraoui J, Canron X, Crisan M, Liu XH, Anjo A, Tolla-Le Port C, Leboeuf M, Charbord P, Bikfalvi A, Uzan G. Human endothelial cells derived from circulating progenitors display specific functional properties as compared to mature vessel wall endothelial cells. Blood. 2003; 20: 20.